The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Sirtuin 3–dependent mitochondrial dynamic improvements protect against acute kidney injury
Open accessAbstract
Acute kidney injury (AKI) is a public health concern with an annual mortality rate that exceeds those of breast and prostate cancer, heart failure, and diabetes combined. Oxidative stress and mitochondrial damage are drivers of AKI-associated pathology; however, the pathways that mediate these events are poorly defined. Here, using a murine cisplatin-induced AKI model, we determined that both oxidative stress and mitochondrial damage are associated with reduced levels of renal sirtuin 3 (SIRT3). Treatment with the AMPK agonist AICAR or the antioxidant agent acetyl-l-carnitine (ALCAR) restored SIRT3 expression and activity, improved renal function, and decreased tubular injury in WT animals, but had no effect in Sirt3-/- mice. Moreover, Sirt3-deficient mice given cisplatin experienced more severe AKI than WT animals and died, and neither AICAR nor ALCAR treatment prevented death in Sirt3-/- AKI mice. In cultured human tubular cells, cisplatin reduced SIRT3, resulting in mitochondrial fragmentation, while restoration of SIRT3 with AICAR and ALCAR improved cisplatin-induced mitochondrial dysfunction. Together, our results indicate that SIRT3 is protective against AKI and suggest that enhancing SIRT3 to improve mitochondrial dynamics has potential as a strategy for improving outcomes of renal injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 8×
“AMPK is an upstream signal of SIRT3 that regulates gene expression and the activity of NAMPT (20, 21) and PGC-1 α (22, 23), and due to the lack of availability of specific SIRT3 activators, we evaluated whether the AMPK activator AICAR protected animals from cisplatin-induced AKI via the induction of SIRT3.”
InfluentialCellular pathophysiology of ischemic acute kidney injury
Bonventre, J. V., & Yang, L. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45161 · Cited by 2,019
Stereological Methods. Practical methods for biological morphometry
Weibel, E. R. (1979) · Academic Press eBooks · Cited by 1,994
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Mitochondrial form and function
Friedman, J. R., & Nunnari, J. (2014) · Nature · doi:10.1038/nature12985 · Cited by 1,803 · cited 2×
“Another element tipping the balance toward fusion is the SIRT3-induced upregulation of OPA1, which mediates the fusion of the inner membrane of the organelle (8, 26, 27).”
Practical methods for biological morphometry
Weibel, E. R. (1979) · Academic Press eBooks · Cited by 1,563
Thadhani, R., Pascual, M., & Bonventre, J. V. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342207 · Cited by 1,417
OPA1 requires mitofusin 1 to promote mitochondrial fusion
Cipolat, S., de Brito, O. M., Dal Zilio, B., & Scorrano, L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407043101 · Cited by 1,300
A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis
Ahn, B.-H., Kim, H.-S., Song, S., Lee, I. H., Liu, J., Vassilopoulos, A., Deng, C.-X., & Finkel, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803790105 · Cited by 1,291
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation
Lombard, D. B., Alt, F. W., Cheng, H.-L., Bunkenborg, J., Streeper, R. S., Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01636-07 · Cited by 1,216
Cited by
Mitochondrial energetics in the kidney
Bhargava, P., & Schnellmann, R. G. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.107 · Cited by 1,334
Mitochondrial dysfunction: mechanisms and advances in therapy
Zong, Y., Li, H., Liao, P., Chen, L., Pan, Y., Zheng, Y., Zhang, C., Liu, D., Zheng, M., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01839-8 · Cited by 1,172
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
The Role of Sirtuins in Antioxidant and Redox Signaling
Singh, C. K., Chhabra, G., Ndiaye, M. A., Garcia-Peterson, L. M., Mack, N. J., & Ahmad, N. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7290 · Cited by 812
Zuk, A., & Bonventre, J. V. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013407 · Cited by 739
NAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Cisplatin nephrotoxicity: new insights and therapeutic implications
Tang, C., Livingston, M. J., Safirstein, R., & Dong, Z. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00631-7 · Cited by 548
PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection
Tran, M. T., Zsengeller, Z. K., Berg, A. H., Khankin, E. V., Bhasin, M. K., Kim, W., Clish, C. B., Stillman, I. E., Karumanchi, S. A., Rhee, E. P., et al. (2016) · Nature · doi:10.1038/nature17184 · Cited by 541
Mitochondrial quality control in kidney injury and repair
Tang, C., Cai, J., Yin, X.-M., Weinberg, J. M., Venkatachalam, M. A., & Dong, Z. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00369-0 · Cited by 513
Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target
Zhang, J., Xiang, H., Liu, J., Chen, Y., He, R.-R., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.45922 · Cited by 503
The hallmarks of mitochondrial dysfunction in chronic kidney disease
Galvan, D. L., Green, N. H., & Danesh, F. R. (2017) · Kidney International · doi:10.1016/j.kint.2017.05.034 · Cited by 447
“OPA1 facilitates the fusing of the inner membrane.”
BackgroundMitochondrial dysfunction in inherited renal disease and acute kidney injury
Emma, F., Montini, G., Parikh, S. M., & Salviati, L. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.214 · Cited by 398
Holditch, S. J., Brown, C. N., Lombardi, A. M., Nguyen, K. N., & Edelstein, C. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123011 · Cited by 377
Wang, Q., Zhang, M., Torres, G., Wu, S., Ouyang, C., Xie, Z., & Zou, M.-H. (2017) · Diabetes · doi:10.2337/db16-0915 · Cited by 370
De novo NAD+ biosynthetic impairment in acute kidney injury in humans
Poyan Mehr, A., Tran, M. T., Ralto, K. M., Leaf, D. E., Washco, V., Messmer, J., Lerner, A., Kher, A., Kim, S. H., Khoury, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0138-z · Cited by 370
Zhai, M., Li, B., Duan, W., Jing, L., Zhang, B., Zhang, M., Yu, L., Liu, Z., Yu, B., Ren, K., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12419 · Cited by 349
Sirtuins in Renal Health and Disease
Morigi, M., Perico, L., & Benigni, A. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017111218 · Cited by 349
Self-citationSirtuins Link Inflammation and Metabolism
Vachharajani, V. T., Liu, T., Wang, X., Hoth, J. J., Yoza, B. K., & McCall, C. E. (2016) · Journal of Immunology Research · doi:10.1155/2016/8167273 · Cited by 320
Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection
Scholz, H., Boivin, F. J., Schmidt-Ott, K. M., Bachmann, S., Eckardt, K.-U., Scholl, U. I., & Persson, P. B. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00394-7 · Cited by 314
Ansari, A., Rahman, M. S., Saha, S. K., Saikot, F. K., Deep, A., & Kim, K. (2017) · Aging Cell · doi:10.1111/acel.12538 · Cited by 306
The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases
Fontecha-Barriuso, M., Martin-Sanchez, D., Martinez-Moreno, J., Monsalve, M., Ramos, A., Sanchez-Niño, M., Ruiz-Ortega, M., Ortiz, A., & Sanz, A. (2020) · Biomolecules · doi:10.3390/biom10020347 · Cited by 294
NAD+ homeostasis in renal health and disease
Ralto, K. M., Rhee, E. P., & Parikh, S. M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0216-6 · Cited by 291
Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., & Sachdev, P. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7269 · Cited by 275
Mitochondria Damage and Kidney Disease
Duann, P., & Lin, P.-H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-55330-6_27 · Cited by 258
Mitochondria in Sepsis-Induced AKI
Sun, J., Zhang, J., Tian, J., Virzì, G. M., Digvijay, K., Cueto, L., Yin, Y., Rosner, M. H., & Ronco, C. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018111126 · Cited by 257
Plasma membrane integrity: implications for health and disease
Ammendolia, D. A., Bement, W. M., & Brumell, J. H. (2021) · BMC Biology · doi:10.1186/s12915-021-00972-y · Cited by 257
Sirt3 promotes antimycobacterial defenses by coordinating mitochondrial and autophagic functions
Kim, T. S., Jin, Y. B., Kim, Y. S., Kim, S., Kim, J. K., Lee, H.-M., Suh, H.-W., Choe, J. H., Kim, Y. J., Koo, B.-S., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1582743 · Cited by 172
Xia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
Protective effects of sirtuin 3 in a murine model of sepsis-induced acute kidney injury
Zhao, W.-Y., Zhang, L., Sui, M.-X., Zhu, Y.-H., & Zeng, L. (2016) · Scientific Reports · doi:10.1038/srep33201 · Cited by 114
Sadhukhan, P., Saha, S., Dutta, S., & Sil, P. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00638 · Cited by 81
“The change in mitochondrial membrane potential was further confirmed by fluorescent microscopy experiments using JC-1 staining (Morigi et al., 2015).”
MethodLei, R., Zhao, F., Tang, C.-Y., Luo, M., Yang, S.-K., Cheng, W., Li, X.-W., & Duan, S.-B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488827 · Cited by 67
Karnewar, S., Vasamsetti, S. B., Gopoju, R., Kanugula, A. K., Ganji, S. K., Prabhakar, S., Rangaraj, N., Tupperwar, N., Kumar, J. M., & Kotamraju, S. (2016) · Scientific Reports · doi:10.1038/srep24108 · Cited by 62
“It is now reasonably known that SIRT3 is involved in mitochondrial biogenesis 35,36 .”
Liu, J., Zong, Z., Zhang, W., Chen, Y., Wang, X., Shen, J., Yang, C., Liu, X., & Deng, H. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.702107 · Cited by 48
Wang, Q., Wu, S., Zhu, H., Ding, Y., Dai, X., Ouyang, C., Han, Y.-M., Xie, Z., & Zou, M.-H. (2017) · Autophagy · doi:10.1080/15548627.2016.1263776 · Cited by 45
Sirtuins, a key regulator of ageing and age-related neurodegenerative diseases
Bhatt, V., & Tiwari, A. K. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2057849 · Cited by 28
Metadata
- Authors
- Morigi, M., Perico, L., Rota, C., Longaretti, L., Conti, S., Rottoli, D., Novelli, R., Remuzzi, G., & Benigni, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 715-726
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1969475086
- Cited by
- 403
- References
- 36
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.